Pancreatic Cancer Research

ResearcherUniversity of LiverpoolNo recent work listed

Richard Charnley

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0906-644X; OpenAlex author ID A5060021577. Sources: OpenAlex.

Their work

Papers
20 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 4 papers · 2015: 2 papers · 2016: 2 papers · 2017: none · 2018: 4 papers · 2019: none · 2020: 4 papers · 2021: 1 paper

Papers 20

  1. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  2. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin defini… Last author DOI 10.1016/j.pan.2020.01.004↗
  3. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  4. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Last author DOI 10.1016/j.suronc.2020.08.031↗
  5. Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001689↗
  6. Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. Co-author DOI 10.1016/j.pan.2018.09.012↗
  7. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  8. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  9. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  10. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biocel.2016.03.009↗
  11. Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2016.264↗
  12. Keap1-Nrf2 signalling in pancreatic cancer. Last author DOI 10.1016/j.biocel.2015.06.017↗
  13. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Co-author DOI 10.1016/j.pan.2014.11.006↗
  14. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.001↗
  15. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Co-author DOI 10.1016/j.surg.2014.02.009↗
  16. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic … Last author DOI 10.1016/j.surg.2014.06.016↗
  17. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  18. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2011.12.020↗
  19. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1097/mpa.0b013e31821fcc3b↗
  20. Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. Last author DOI 10.1155/2011/215985↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John P. Neoptolemos · 9 shared papers, 2014–2021 · strength 0.44
  2. Beate Haugk · 5 shared papers, 2012–2020 · strength 0.38
  3. Stuart Michael Robinson · 4 shared papers, 2012–2020 · strength 0.33
  4. Paula Ghaneh · 5 shared papers, 2014–2021 · strength 0.29
  5. Christopher Michael Halloran · 5 shared papers, 2014–2021 · strength 0.29
  6. Markus Wolfgang Büchler · 6 shared papers, 2014–2021 · strength 0.27
  7. John A. G. Moir · 3 shared papers, 2020 · strength 0.27
  8. Derek Manas · 3 shared papers, 2012–2020 · strength 0.25
  9. Alan Anthoney · 4 shared papers, 2014–2021 · strength 0.23
  10. Bengt L. G. Glimelius · 4 shared papers, 2014–2021 · strength 0.23
  11. Daniel H. Palmer · 4 shared papers, 2014–2021 · strength 0.23
  12. Niall Christopher Tebbutt · 4 shared papers, 2014–2021 · strength 0.23
  13. Julia V. Mayerle · 4 shared papers, 2014–2021 · strength 0.23
  14. William Greenhalf · 4 shared papers, 2014–2021 · strength 0.23
  15. Juan W. Valle · 4 shared papers, 2014–2021 · strength 0.23
  16. Eithne Costello · 4 shared papers, 2014–2021 · strength 0.23
  17. Christos Dervenis · 6 shared papers, 2014–2018 · strength 0.23
  18. Steven Alan White · 3 shared papers, 2012–2020 · strength 0.22
  19. David Goldstein · 3 shared papers, 2018–2021 · strength 0.21
  20. Nils O. Elander · 3 shared papers, 2018–2021 · strength 0.21
  21. Karen Aughton · 3 shared papers, 2018–2021 · strength 0.21
  22. Markus M. Lerch · 3 shared papers, 2018–2021 · strength 0.21
  23. Claudio Bassi · 5 shared papers, 2014–2020 · strength 0.20
  24. Jelena Mann · 2 shared papers, 2016–2020 · strength 0.19
  25. Giuseppe Malleo · 2 shared papers, 2020 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.